Drug resistance in mycobacterium tuberculosis: Molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness

Chest

Volumn 147, Issue 4, 2015, Pages 1135-1143

  Miotto, Paolo ^a   Cirillo, Daniela M ^a   Migliori, Giovanni Battista ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CHROMOSOME MUTATION; CLINICAL DECISION MAKING; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENETIC ANALYSIS; HOST PATHOGEN INTERACTION; INFLAMMATION; MEMBRANE DAMAGE; MOLECULAR DIAGNOSIS; MOLECULAR DYNAMICS; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; POINT MUTATION; PRIORITY JOURNAL; TUBERCULOSIS; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84927142797     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1286     Document Type: Article

References (107)

1. Organization WH. Global Tuberculosis Report 2013. Geneva, Switzerland: World Health Organization; 2013.
2. Diel R , Vandeputte J , de Vries G , Stillo J , Wanlin M , Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014; 43 (2): 554-565.
3. D'Ambrosio L , Dara M , Tadolini M ,et al; European national programme representatives. Tuberculosiselimination: theory and practice in Europe. Eur Respir J. 2014; 43 (5): 1410-1420.
4. Sotgiu G , Mauch V , Migliori GB , Benedetti A. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J. 2014; 43 (6): 1563-1566.
5. Law S , Benedetti A , Oxlade O , Schwartzman K , Menzies D. Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. Eur Respir J. 2014; 43 (2): 566-581.
6. Esposito S , D'Ambrosio L , Tadolini M ,et al. ERS/WHO Tuberculosis Consilium assistance withextensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J. 2014; 44 (3): 811-815.
7. Chang KC , Leung CC , Yew WW ,et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012; 56 (11): 5465-5475.
8. Lipsitch M , Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in theevolution of drug resistance. Int J Tuberc Lung Dis. 1998; 2 (3): 187-199.
9. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012; 55 (2): 169-177.
10. Akkerman OW , van Altena R , Klinkenberg T ,et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J. 2013; 42 (6): 1750-1752.
11. Hermsen R , Deris JB , Hwa T. On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc Natl Acad Sci U S A. 2012; 109 (27): 10775-10780.
12. Dartois V , Barry CE III. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett. 2013; 23 (17): 4741-4750.
13. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002; 46 (2): 267-274.
14. Schmalstieg AM , Srivastava S , Belkaya S ,et al. The antibiotic resistance arrow of time:efflux pump induction is a general first step in theevolution of mycobacterial drug resistance. Antimicrob Agents Chemother. 2012; 56 (9): 4806-4815.
15. Wrande M , Roth JR , Hughes D. Accumulation of mutants in "aging" bacterial colonies is due to growth under selection, not stress-induced mutagenesis. Proc Natl Acad Sci U S A. 2008; 105 (33): 11863-11868.
16. Webber MA , Ricci V , Whitehead R ,et al. Clinically relevant mutant DNA gyrase alters supercoiling, changes the transcriptome, and confers multidrug resistance. MBio. 2013; 4 (4):piie00273-13.
17. Katz S, Hershberg R. Elevated mutagenesis does notexplain the increased frequency of antibiotic resistant mutants in starved aging colonies. P LoS Genet. 2013; 9 (11):e1003968.
18. Li X , Tao J , Han J ,et al. The gain of hydrogen peroxide resistance benefits growth fitness in mycobacteria under stress. Protein Cell. 2014; 5 (3): 182-185.
19. Bhaskar A , Chawla M , Mehta M ,et al. Reengineering redox sensitive GFP to measure mycothiol redox potential of Mycobacterium tuberculosis during infection. PLoS Pathog. 2014; 10 (1):e1003902.
20. Schoeffler AJ , Berger JM. DNA topoisomerases: harnessing and constrainingenergy to govern chromosome topology. Q Rev Biophys. 2008; 41 (1): 41-101.
21. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003; 3 (3): 249-282.
22. Drlica K, Malik M, Kerns RJ , Zhao X. Quinolone-mediated bacterial death. A ntimicrob Agents Chemother. 2008; 52 (2): 385-392.
23. Kumar R , Madhumathi BS , Nagaraja V. Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Antimicrob Agents Chemother. 2014; 58 (4): 2013-2020.
24. Kohanski MA , Dwyer DJ , Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010; 8 (6): 423-435.
25. Piton J , Petrella S , Delarue M ,et al. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS ONE. 2010; 5 (8):e12245.
26. Vetting MW , Hegde SS , Fajardo JE ,et al. Pentapeptide repeat proteins. B iochemistry. 2006; 45 (1): 1-10.
27. Hegde SS , Vetting MW , Roderick SL ,et al. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science. 2005; 308 (5727): 1480-1483.
28. Méns A , Matrat S , Aubry A ,et al. The pentapeptide repeat proteins MfpAMt and QnrB4exhibit oppositeeffects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex. J Bacteriol. 2009; 191 (5): 1587-1594.
29. Tao J , Han J , Wu H,et al. Mycobacterium fluoroquinolone resistance protein B, a novel small GTPase, is involved in the regulation of DNA gyrase and drug resistance. Nucleic Acids Res. 2013; 41 (4): 2370-2381.
30. Sarathy JP , Lee E , Dartois V. Polyamines inhibit porin-mediated fluoroquinolone uptake in mycobacteria. PLoS ONE. 2013; 8 (6):e65806.
31. Goytia M, Shafer WM. Polyamines can increase resistance of Neisseria gonorrhoeae to mediators of the innate human host defense. I nfect Immun. 2010; 78 (7): 3187-3195.
32. Park MH , Igarashi K. Polyamines and their metabolites as diagnostic markers of human diseases. Biomol Ther. 2013; 21 (1): 1-9.
33. Maruri F , Sterling TR , Kaiga AW ,et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012; 67 (4): 819-831.
34. Lau RW , Ho PL , Kao RY ,et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother. 2011; 55 (2): 608-614.
35. Malik S , Willby M , Sikes D , Tsodikov OV , Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS ONE. 2012; 7 (6):e39754.
36. Aubry A, Veziris N, Cambau E, Truff ot-Pernot C, Jarlier V , Fisher LM. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutantenzymes. Antimicrob Agents Chemother. 2006; 50 (1): 104-112.
37. Zhang Y , Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003; 7 (1): 6-21.
38. Lu P , Haagsma AC , Pham H,et al. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels. Antimicrob Agents Chemother. 2011; 55 (11): 5354-5357.
39. Shi W , Zhang X, Jiang X,et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. S cience. 2011; 333 (6049): 1630-1632.
40. Zhang S , Chen J , Shi W ,et al. Mutations in panDencoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. E merging Microbes & Infections. 2013; 2:e34.
41. Zhang H , Deng JY , Bi LJ ,et al. Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS J. 2008; 275 (4): 753-762.
42. Napiórkowska A , Rüsch-Gerdes S , Hillemann D , Richter E , Augustynowicz-Kopeć E. Characterisation of pyrazinamideresistant Mycobacterium tuberculosis strains isolated in Poland and Germany. I nt J Tuberc Lung Dis. 2014; 18 (4): 454-460.
43. Petrella S , Gelus-Ziental N , Maudry A , Laurans C , Boudjelloul R , Sougakoff W. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS ONE. 2011; 6 (1):e15785.
44. Sheen P , Ferrer P , Gilman RH ,et al. Role of metal ions on the activity of Mycobacterium tuberculosis pyrazinamidase. Am J Trop Med Hyg. 2012; 87 (1): 153-161.
45. Feuerriegel S , Koser CU , Richter E ,et al. M ycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother. 2013; 68 (6): 1439-1440.
46. Mphahlele M, Syre H, Valvatne H,et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol. 2008; 46 (10): 3459-3464.
47. Sheen P , Ferrer P , Gilman RH ,et al. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2009; 89 (2): 109-113.
48. Cui Z , Wang J , Lu J , Huang X , Zheng R , Hu Z. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J Clin Microbiol. 2013; 51 (5): 1374-1380.
49. Feuerriegel S, Köser CU , Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother. 2014; 69 (5): 1205-1210.
50. Personne Y , Parish T. M ycobacterium tuberculosis possesses an unusual tmRNA rescue system. Tuberculosis (Edinb). 2014; 94 (1): 34-42.
51. Alexander DC , Ma JH , Guthrie JL , Blair J , Chedore P , Jamieson FB. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol. 2012; 50 (11): 3726-3728.
52. Tan Y , Hu Z , Zhang T ,et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014; 52 (1): 291-297.
53. Gouzy A , Poquet Y , Neyrolles O. A central role for aspartate in Mycobacterium tuberculosis physiology and virulence. Front Cell Infect Microbiol. 2013; 3: 68.
54. Dowdy DW , Cattamanchi A , Steingart KR , Pai M. Is scale-up worth it? Challenges ineconomic analysis of diagnostic tests for tuberculosis. PLoS Med. 2011; 8 (7):e1001063.
55. Winetsky DE , Negoescu DM , DeMarchis EH,et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med. 2012; 9 (11): e1001348.
56. Shah M , Chihota V , Coetzee G , Churchyard G , Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drugresistant tuberculosis in South Africa. BMC Infect Dis. 2013; 13: 352.
57. Choi HW , Miele K , Dowdy D , Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013; 17 (10): 1328-1335.
58. Theron G , Zijenah L , Chanda D ,et al; TB-NEAT team. Feasibility, accuracy, and clinicaleffect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014; 383 (9915): 424-435.
59. Dowdy DW , van't Hoog A , Shah M , Cobelens F. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. Int J Tuberc Lung Dis. 2014; 18 (6): 647-654.
60. Giannoni F , Iona E , Sementilli F ,et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. A ntimicrob Agents Chemother. 2005; 49 (7): 2928-2933.
61. Hillemann D , Rüsch-Gerdes S , Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacincapreomycin, andethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2009; 47 (6): 1767-1772.
62. Ando H , Mitarai S , Kondo Y ,et al. Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol. 2011; 60 (pt 2): 184-188.
63. Mitarai S , Kato S , Ogata H ,et al. Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2012; 50 (3): 884-890.
64. Zimenkov DV , Antonova OV , Kuz'min AV ,et al. Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays. BMC Infect Dis. 2013; 13: 240.
65. World Health Organization. The Use of Molecular Line Probe Assay For the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs. Geneva, Switzerland: World Health Organization; 2013: 1-52.
66. Guyatt GH , Oxman AD , Vist GE ,et al; GRADE Working Group. GRADE: anemerging consensus on rating quality ofevidence and strength of recommendations. BMJ. 2008; 336 (7650): 924-926.
67. Mohamed AM, Bastola DR , Morlock GP , Cooksey RC , Hinrichs SH. Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high-performance liquid chromatography. J Clin Microbiol. 2004; 42 (3): 1016-1023.
68. Wade MM , Volokhov D , Peredelchuk M , Chizhikov V , Zhang Y. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis . 2004; 49 (2): 89-97 .
69. McCammon MT , Gillette JS , Thomas DP ,et al . Detection by denaturing gradient gelelectrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region . Antimicrob Agents Chemother . 2005; 49 (6): 2210-2217 .
70. Denkin S , Volokhov D , Chizhikov V , Zhang Y . Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis . J Med Microbiol . 2005; 54 (pt 12): 1127-1131 .
71. Sekiguchi J , Nakamura T , Miyoshi-Akiyama T ,et al . Development andevaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains . J Clin Microbiol . 2007; 45 (9): 2802-2807 .
72. Sheen P , Méndez M , Gilman RH ,et al . Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients . J Clin Microbiol . 2009; 47 (9): 2937-2943 .
73. Chang KC , Yew WW , Zhang Y . Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with metaanalyses . A ntimicrob Agents Chemother . 2011; 55 (10): 4499-4505 .
74. Horne DJ , Pinto LM , Arentz M ,et al . Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs . J Clin Microbiol . 2013; 51 (2): 393-401 .
75. Köser CU , Comas I , Feuerriegel S ,et al. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay . Tuberculosis (Edinb) . 2014; 94 (4): 451-453 .
76. Daum LT , Rodriguez JD , Worthy SA ,et al . Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains . J Clin Microbiol . 2012; 50 (12): 3831-3837 .
77. Daum LT , Fourie PB , Bhattacharyya S ,et al . Next-generation sequencing for identifying pyrazinamide resistance in Mycobacterium tuberculosis . C lin Infect Dis . 2014; 58 (6): 903-904 .
78. Daum LT , Fischer GW , Sromek J ,et al . Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants residing in the USA using Ion Torrent full-gene sequencing . Epidemiol Infect . 2014; 142 (6): 1328-1333
79. Plinke C, Cox HS, Kalon S, Doshetov D , Rüsch-Gerdes S, Niemann S. Tuberculosisethambutol resistance: concordance between phenotypic and genotypic test results . Tuberculosis (Edinb) . 2009; 89 (6): 448-452 .
80. Rigouts L , Gumusboga M , de Rijk WB ,et al . Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations . J Clin Microbiol . 2013; 51 (8): 2641-2645 .
81. Miotto P , Cabibbe AM, Mantegani P ,et al . GenoType MTBDRsl performance on clinical samples with diverse genetic background . Eur Respir J . 2012; 40 (3): 690-698 .
82. Hoffner S , Angeby K , Sturegård E ,et al . Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedishexperience . Int J Tuberc Lung Dis . 2013; 17 (11): 1486-1490 .
83. Piersimoni C, Mustazzolu A, Giannoni F , Bornigia S, Gherardi G, Fattorini L . Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum . J Clin Microbiol . 2013; 51 (1): 291-294 .
84. Chernyaeva E , Fedorova E , Zhemkova G , Korneev Y , Kozlov A . Characterization of multiple andextensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels . T uberculosis (Edinb) . 2013; 93 (3): 291-295 .
85. Nebenzahl-Guimaraes H, Jacobson KR , Farhat MR , Murray MB . Systematic review of allelicexchangeexperiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis . J Antimicrob Chemother . 2014; 69 (2): 331-342 .
86. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J . Geneticevaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin . BMC Microbiol . 2009; 9: 10 .
87. Feuerriegel S , Oberhauser B , George AG ,et al . Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting . BMC Microbiol . 2012; 12: 90 .
88. Van Deun A , Aung KJ , Bola V ,et al . Rifampin drug resistance tests for tuberculosis: challenging the gold standard . J Clin Microbiol . 2013; 51 (8): 2633-2640 .
89. Ocheretina O , Escuyer VE , Mabou MM ,et al . Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results . PLoS ONE . 2014; 9 (3):e90569 .
90. Suzuki Y , Nakajima C, Tamaru A, Kim H, Matsuba T , Saito H. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance . Int J Antimicrob Agents . 2012; 39 (5): 435-439 .
91. Yin X , Yu Z . Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China . J Infect . 2010; 61 (2): 150-154 .
92. Werngren J , Stureg?d E , Jur?n P , Ängeby K , Hoff ner S, Schön T . Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing . Antimicrob Agents Chemother . 2012; 56 (3): 1253-1257 .
93. Williamson DA , Roberts SA , Bower JE ,et al . Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis . I nt J Tuberc Lung Dis . 2012; 16 (2): 216-220 .
94. Bodmer T , Zücher G , Imboden P , Telenti A . Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis . J Antimicrob Chemother . 1995; 35 (2): 345-348 .
95. Williams DL , Spring L , Collins L ,et al . Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis . A ntimicrob Agents Chemother . 1998; 42 (7): 1853-1857 .
96. Uzun M, Erturan Z, Anʇ O . Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains . Int J Tuberc Lung Dis . 2002; 6 (2): 164-165 .
97. Jamieson FB , Guthrie JL , Neemuchwala A ,et al . Profiling of rpoB Mutations and MICs to rifampicin and rifabutin in Mycobacterium tuberculosis . J Clin Microbiol . 2014; 52 (5): 2157-2162 .
98. Fenner L, Egger M, Bodmer T ,et al; Swiss HIV Cohort Study and the Swiss Molecular Epidemiology of Tuberculosis Study Group . Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis . A ntimicrob Agents Chemother . 2012; 56 (6): 3047-3053 .
99. Huyen MN , Cobelens FG , Buu TN ,et al . Epidemiology of isoniazid resistance mutations and theireffect on tuberculosis treatment outcomes . A ntimicrob Agents Chemother . 2013; 57 (8): 3620-3627 .
100. Wang TY , Lin SM , Shie SS ,et al . Clinical characteristics and treatment outcomes of patients with low-and high-concentration isoniazid-monoresistant tuberculosis . PLoS ONE . 2014; 9 (1):e86316 .
101. Georghiou SB , Magana M, Garfein RS, Catanzaro DG , Catanzaro A , Rodwell TC . Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review . PLoS ONE . 2012; 7 (3):e33275 .
102. Jo KW , Lee SD , Kim WS , Kim DS , Shim TS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrugresistant tuberculosis . Int J Tuberc Lung Dis . 2014; 18 (1): 39-43 .
103. Müller B , Borrell S , Rose G , Gagneux S . The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis . Trends Genet . 2013; 29 (3): 160-169 .
104. Arnvig KB , Comas I , Thomson NR ,et al . Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcriptome of Mycobacterium tuberculosis . P LoS Pathog . 2011; 7 (11):e1002342 .
105. Pellin D , Miotto P , Ambrosi A, Cirillo DM , Di Serio C. A genomewide identification analysis of small regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and conservation analysis . PLoS ONE . 2012; 7 (3):e32723 .
106. Miotto P , Forti F , Ambrosi A,et al . Genome-wide discovery of small RNAs in Mycobacterium tuberculosis . P LoS ONE . 2012; 7 (12): e51950 .
107. Zhang H , Li D , Zhao L ,et al . Genome sequencing of 161 Mycobac terium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance . Nat Genet . 2013; 45 (10): 1255-1260 .